Stefanie Flohr
Basel, BS, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Strategic Key Performance Indicators for AI in Lead Optimization.
Journal: ChemMedChem
Published: November 28, 2025
Low-molecular weight inhibitors of the alternative complement pathway.
Journal: Immunological reviews
Published: October 11, 2022
Discovery of 4-((2S,4S)-4-Ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (LNP023), a Factor B Inhibitor Specifically Designed To Be Applicable to Treating a Diverse Array of Complement Mediated Diseases.
Journal: Journal of medicinal chemistry
Published: February 20, 2020
Design, Synthesis, and Preclinical Characterization of Selective Factor D Inhibitors Targeting the Alternative Complement Pathway.
Journal: Journal of medicinal chemistry
Published: April 18, 2019
Small-molecule factor B inhibitor for the treatment of complement-mediated diseases.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: March 31, 2019
Discovery of Highly Potent and Selective Small-Molecule Reversible Factor D Inhibitors Demonstrating Alternative Complement Pathway Inhibition in Vivo.
Journal: Journal of medicinal chemistry
Published: June 17, 2017
Small-molecule factor D inhibitors targeting the alternative complement pathway.
Journal: Nature chemical biology
Published: May 20, 2016
Plasma contact system activation drives anaphylaxis in severe mast cell-mediated allergic reactions.
Plasma contact system activation drives anaphylaxis in severe mast cell-mediated allergic reactions.
Journal: The Journal of allergy and clinical immunology
Published: January 10, 2014
Discovery of C-(1-aryl-cyclohexyl)-methylamines as selective, orally available inhibitors of dipeptidyl peptidase IV.
Journal: Bioorganic & medicinal chemistry letters
Published: November 04, 2013
Showing 1-9 of 9
Last Updated: 09/26/2026